MCAM and malignant peritoneal mesothelioma: Our key contributions include the confirmation of CD146 as a viable target for malignant peritoneal mesothelioma (MPM), preclinical evaluation of 212Pb-TCMC-OI-3, and demonstration of its potential in terms of affinity, selectivity, internalization, and therapeutic efficacy.